Naar www.iknl.nl
- Gastroenterologie > Maagcarcinoom
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Laatst gewijzigd: 2017-03-01, Versie: 2.2, Verantwoording: Landelijke werkgroep Gastro-intestinale Tumoren, Type: Landelijke richtlijn

Referentielijst

1 - Abe N (2002)
Abe N, Watanabe T, Suzuki K, Machida H, Toda H, Nakaya Y, Masaki T, Mori T, Sugiyama M, Atomi Y. Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am J Surg 2002; 183(2):168-72.
 
2 - Adachi Y (2000)
Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000 Oct 1;89(7):1418-24
 
3 - Ahmed N (2004)
Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S. Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 2004;(3):CD003445.
 
4 - Ajani JA (2004)
Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22(14):2774-80.
 
5 - Ajani JA (2007)
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van CE. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma. the V-325 Study Group. J Clin Oncol 2007; 25(22):3205-9.
 
6 - Ajani JA (2007)
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van CE. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma. the V-325 Study Group. J Clin Oncol 2007; 25(22):3210-6.
 
7 - Al-Batran SE (2008)
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin. a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26(9):1435-42.
 
8 - Armbrecht U (1988)
Armbrecht U, Lundell L, Stockbrugger RW. The benefit of pancreatic enzyme substitution after total gastrectomy. Alliment Pharmacol Ther 1988 Dec,2(6):493-500.
 
9 - An JY (2007)
An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion. analysis of a single institutional experience. Ann Surg 2007; 246(5):749-53.
 
10 - Baba H (1989)
Baba H, Korenaga D, Okamura T, Saito A, Sugimachi K. Prognostic factors in gastric cancer with serosal invasion. Univariate and multivariate analyses. Arch Surg 1989 Sep;124(9):1061-4.
 
11 - Bachmann MO (2002)
Bachmann MO, Alderson D, Edwards D, Wotton S, Bedford C, Peters TJ, Harvey IM. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002; 89(7):914-22.
 
12 - Bae JM (1998)
Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer patients after total gastrectomy. World J Surg 1998; 22(3):254-60.
 
13 - Bajetta E (2002)
Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM. Adjuvant chemotherapy in gastric cancer. 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13(2):299-307.
 
14 - Bassily R (2000)
Bassily R, Smallwood RA, Crotty B. Risk of gastric cancer is not increased after partial gastrectomy. J Gastroenterol Hepatol. 2000 Jul;15(7):762-5.
 
15 - Becker K (2003)
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al. Histomorpholog and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003 Oct 1;98(7):1521-30
 
16 - Bennett JJ (2005)
Bennett JJ, Gonen M, D'Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg 2005; 201(4):503-10.
 
17 - Bentrem D (2007)
Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 2007; 14(6):1853-9.
 
18 - Birkmeyer JD (2002)
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346(15):1128-37.
 
19 - Blackshaw GR (2003)
Blackshaw GR, Barry JD, Edwards P, Allison MC, Thomas GV, Lewis WG. Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. Gastric Cancer 2003; 6(4):225-9.
 
20 - Blackshaw GR (2005)
Blackshaw GR, Stephens MR, Lewis WG, Boyce J, Barry JD, Edwards P, Allison MC, Thomas GV. Progressive CT system technology and experience improve the perceived preoperative stage of gastric cancer. Gastric Cancer 2005; 8(1):29-34.
 
21 - Bohner H (2000)
Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer--is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000; 47(35):1489-94.
 
22 - Bonenkamp JJ (1999)
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999 Mar 25;340(12):908-14.
 
23 - Bonenkamp JJ (2001)
Bonenkamp JJ, Sasako M, Hermans J, Van de Velde CJ. Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001; 48(41):1219-21.
 
24 - Bouche O (2005)
Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer. 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16(9):1488-97.
 
25 - Bozzetti F (1990)
Bozzetti F, Ravera E, Cozzaglio L, Dossena G, Agradi E, Bonfanti G, Koukouras D, Gennari L. Comparison of nutritional status after total or subtotal gastrectomy. Nutrition 1990; 6(5):371-5.
 
26 - Bozzetti F (1997)
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L. Total versus subtotal gastrectomy. surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg 1997; 226(5):613-20.
 
27 - Bozzetti F (1999)
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer. five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230(2):170-8.
 
28 - Bozzetti F (2001)
Bozzetti F. Principles of surgical radicality in the treatment of gastric cancer. Surg Oncol Clin N Am. 2001 Oct;10(4):833-54, ix.
 
29 - Braga M (2001)
Braga M, Gianotti L, Gentilini O, Parisi V, Salis C, Di C, V. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Crit Care Med 2001; 29(2):242-8.
 
30 - Bragelmann R (1999)
Bragelmann R, Armbrecht U, Rosemeyer D, Schneider B, Zilly W, Stockbrugger RW. The effect of pancreatic enzyme supplementation in patients with steatorrhoea after total gastrectomy. Eur J Gastroenterol Hepatol 1999; 11(3):231-7.
 
31 - Burgers JS (2007)
Burgers JS, Wittenberg J, Kallewaard M, van Croonenborg JJ, van Barneveld TA, van Everdingen JJ. [Relationship between volume and quality of care for surgical interventions; results of a literature review]. Ned Tijdschr Geneeskd 2007; 151(38):2105-10.
 
32 - Callahan MA (2003)
Callahan MA, Christos PJ, Gold HT, Mushlin AI, Daly JM. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. Ann Surg 2003; 238(4):629-36.
 
33 - Carneiro F (1997)
Carneiro F. Classification of gastric carcinomas. Current Diag Pathol 1997;4(1):51-9.
 
34 - Carneiro F (2004)
Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P,et al . Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203(2):681-7.
 
35 - Casaretto L (2006)
Casaretto L, Sousa PL, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer. a meta-analysis. Braz J Med Biol Res 2006; 39(4):431-40.
 
36 - Cascinu S (2007)
Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99(8):601-7.
 
37 - Celen O (2007)
Celen O, Yildirim E, Berberoglu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol 2007 Aug 1;96(2):95-101.
 
38 - Chang HM (2002)
Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol 2002; 13(11):1779-85.
 
39 - Chao A (2002)
Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II. Int J Cancer. 2002 Oct 1;101(4):380-9.
 
40 - Chau I (2004)
Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22(12):2395-2403.
 
41 - Chen DW (2005)
Chen DW, Wei FZ, Zhang YC, Ou JM, Xu J. Role of enteral immunonutrition in patients with gastric carcinoma undergoing major surgery. Asian J Surg 2005; 28(2):121-4.
 
42 - Chipponi J (2004)
Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fagniez PL, Gainant A. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004; 187(3):440-5.
 
43 - Choi SR (2006)
Choi SR, Jang JS, Lee JH, Roh MH, Kim MC, Lee WS, Qureshi W. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 2006; 51(11):2081-6.
 
44 - Coburn NG (2006)
Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006 Nov 1;107(9):2143-51
 
45 - Csendes A (2002)
Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131(4):401-7.
 
46 - Cunningham D (2005)
Cunningham D, Jost LM, Purkalne G, Oliveira J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 2005; 16 Suppl 1:i22-i23.
 
47 - Cunningham D (2006)
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de, Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC TP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1):11-20.
 
48 - Cunningham D (2008)
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1):36-46.
 
49 - Damhuis RA (2002)
Damhuis RA, Meurs CJ, Dijkhuis CM, Stassen LP, Wiggers T. Hospital volume and post-operative mortality after resection for gastric cancer. Eur J Surg Oncol 2002; 28(4):401-5.
 
50 - Dassen AE (2009)
Dassen AE, Lips DJ, HoekstraCJ, Pruijt JFM , Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009; 35: 449-55.
 
51 - De Graaf GW (2007)
De Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33(8):988-92.
 
52 - De Manzoni G (2003)
De Manzoni G, Verlato G, Roviello F, Di LA, Marrelli D, Morgagni P, Pasini F, Saragoni L, Tomezzoli A. Subtotal versus total gastrectomy for T3 adenocarcinoma of the antrum. Gastric Cancer 2003; 6(4):237-42.
 
53 - De Potter T (2002)
De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29(4):525-9.
 
54 - De Vita F (2007)
De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007; 18 Suppl 6:vi120-vi123.
 
55 - Di Bartolomeo M (2006)
Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoni A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E, Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology 2006; 71(5-6):341-6.
 
56 - Doglietto GB (1999)
Doglietto GB, Pacelli F, Caprino P, Alfieri S, Carriero C, Malerba M, Crucitti F. Palliative surgery for far-advanced gastric cancer. a retrospective study on 305 consecutive patients. Am Surg 1999; 65(4):352-5.
 
57 - Doglietto GB (2004)
Doglietto GB, Papa V, Tortorelli AP, Bossola M, Covino M, Pacelli F. Nasojejunal tube placement after total gastrectomy. a multicenter prospective randomized trial. Arch Surg 2004; 139(12):1309-13.
 
58 - Dormann A (2004)
Dormann A, Meisner S, Verin N, Wenk LA. Self-expanding metal stents for gastroduodenal malignancies. systematic review of their clinical effectiveness. Endoscopy 2004; 36(6):543-50.
 
59 - Duffour J (2006)
Duffour J, Bouche O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, Francois E, Ychou M. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res 2006; 26(5B):3877-83.
 
60 - Earle CC (1999)
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients. revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7):1059-64.
 
61 - Earle CC (2002)
Earle CC, Maroun J, Zuraw L. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Can J Surg 2002; 45(6):438-46.
 
62 - Earle CC (2003)
Earle CC, Maroun J, Zuraw L and members of the Gastrointestinal Cancer Disease Site Group. Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer. Practice Guideline Report #2-14, 2003 http://www.cancercare.on.ca/pdf/pebc2-14s.pdf.
 
63 - Edwards P (2004)
Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer 2004; 90(10):1888-92.
 
64 - Engel LS (2003)
Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003 Sept 17;95(18):1404-13.
 
65 - Farreras N (2005)
Farreras N, Artigas V, Cardona D, Rius X, Trias M, Gonzalez JA. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr 2005; 24(1):55-65.
 
66 - Finlayson EV (2003)
Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery. A national study. Arch Surg 2003; 138(7):721-5.
 
67 - Fitzgerald RC (2004)
Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut. 2004 Jun;53(6):775-8.
 
68 - Fiorica F (2007)
Fiorica F, Cartei F, Enea M, Licata A, Cabibbo G, Carau B, Liboni A, Ursino S, Camma C. The impact of radiotherapy on survival in resectable gastric carcinoma. A meta-analysis of literature data. Cancer Treat Rev 2007; 33(8):729-40.
 
69 - Folli S (2001)
Folli S, Morgagni P, Roviello F, De MG, Marrelli D, Saragoni L, Di LA, Gaudio M, Nanni O, Carli A, Cordiano C, Dell'Amore D, Vio A. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001; 31(10):495-9.
 
70 - Fu QG (2002)
Fu QG, Meng FD, Shen XD, Guo RX. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol 2002; 8(6):1019-22.
 
71 - Fuccio L (2007)
Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007 Jan 15;25(2):133-41.
 
72 - Fujimura T (2002)
Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, Kayahara M, Shimizu K, Ohta T, Miwa K. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy 2002; 34(7):569-74.
 
73 - Fukase K (2008)
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008 Aug 2;372(9636):392-7.
 
74 - Gianotti L (1997)
Gianotti L, Braga M, Vignali A, Balzano G, Zerbi A, Bisagni P, Di C, V. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg 1997; 132(11):1222-9.
 
75 - Giuliani A (2004)
Giuliani A, Caporale A, Corona M, Di BM, Demoro M, Ricciardulli T et al. Lymphadenectomy in gastric cancer: influence on prognosis of lymph node count. J Exp Clin Cancer Res 2004 June;23(2):215-24.
 
76 - Gotoda T (2000)
Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer. estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3(4):219-25.
 
77 - Gotoda T (2000)
Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer. estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3(4):219-25.
 
78 - Gotoda T (2006)
Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006a; 41(10):929-42.
 
79 - Gotoda T (2006)
Gotoda T. Endoscopic resection of early gastric cancer. The Japanese perspective. Curr Opin Gastroenterol 2006b; 22(5):561-9.
 
80 - Gotoda T (2007)
Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer 2007; 10(1):1-11.
 
81 - Gouzi JL (1989)
Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, Paquet JC, Hay JM. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989; 209(2):162-6.
 
82 - Hallissey MT (1994)
Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer. five-year follow-up. Lancet 1994; 343(8909):1309-12.
 
83 - Halm EA (2002)
Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137(6):511-20.
 
84 - Hanazaki K (1999)
Hanazaki K, Sodeyama H, Mochizuki Y, Machida T, Yokoyama S, Sode Y, Wakabayashi M, Kawamura N, Miyazaki T, Amano J. Efficacy of extended lymphadenectomy in the noncurative gastrectomy for advanced gastric cancer. Hepatogastroenterology 1999; 46(28):2677-82.
 
85 - Hanazaki K (2001)
Hanazaki K, Sodeyama H, Mochizuki Y, Igarashi J, Yokoyama S, Sode Y, Wakabayashi M, Kawamura N, Miyazaki T. Palliative gastrectomy for advanced gastric cancer. Hepatogastroenterology 2001; 48(37):285-9.
 
86 - Hannan EL (2002)
Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131(1):6-15.
 
87 - Hartgrink HH (2002)
Hartgrink HH, Putter H, Klein KE, Bonenkamp JJ, van de Velde CJ. Value of palliative resection in gastric cancer. Br J Surg 2002; 89(11):1438-43.
 
88 - Hartgrink HH (2004)
Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der BJ, van Krieken JH. Neo-adjuvant chemotherapy for operable gastric cancer. long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30(6):643-9.
 
89 - Hartgrink HH (2004)
Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein KE, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer. who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22(11):2069-77.
 
90 - Hermans J (1993)
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer. meta-analysis of randomized trials. J Clin Oncol 1993; 11(8):1441-7.
 
91 - Heslin MJ (1997)
Heslin MJ, Latkany L, Leung D, Brooks AD, Hochwald SN, Pisters PW, Shike M, Brennan MF. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann Surg 1997; 226(4):567-77.
 
92 - Hizawa K (2002)
Hizawa K, Iwai K, Esaki M, Matsumoto T, Suekane H, Iida M. Is endoscopic ultrasonography indispensable in assessing the appropriateness of endoscopic resection for gastric cancer? Endoscopy 2002;34(12):973-8.
 
93 - Hosono S (2007)
Hosono S, Ohtani H, Arimoto Y, Kanamiya Y. Endoscopic stenting versus surgical gastroenterostomy for palliation of malignant gastroduodenal obstruction. a meta-analysis. J Gastroenterol 2007; 42(4):283-90.
 
94 - Hu J-K (2002)
Hu J-K, Chen Z-X, Zhou Z-G, Zhang B, Tian J,Chen J-P et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterology 2002(8):1023-8.
 
95 - Huscher CG (2005)
Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di PM, Recher A, Ponzano C. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer. five-year results of a randomized prospective trial. Ann Surg 2005; 241(2):232-7.
 
96 - Hyltander A (2005)
Hyltander A, Bosaeus I, Svedlund J, Liedman B, Hugosson I, Wallengren O, Olsson U, Johnsson E, Kostic S, Henningsson A, Korner U, Lundell L, Lundholm K. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery. A randomized study. Clin Gastroenterol Hepatol 2005; 3(5):466-74.
 
97 - Hyung WJ (2004)
Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol 2004; 85(4):181-5.
 
98 - Ishikawa S (2007)
Ishikawa S, Togashi A, Inoue M, Honda S, Nozawa F, Toyama E, Miyanari N, Tabira Y, Baba H. Indications for EMR/ESD in cases of early gastric cancer. relationship between histological type, depth of wall invasion, and lymph node metastasis. Gastric Cancer 2007; 10(1):35-8.
 
99 - Iwase K (2002)
Iwase K, Higaki J, Yoon HE, Mikata S, Miyazaki M, Kamiike W. Reduced thiamine (vitamin B1) levels following gastrectomy for gastric cancer. Gastric Cancer 2002; 5(2):77-82.
 
100 - Janunger KG (2002)
Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer. A review and updated meta-analysis. Eur J Surg 2002; 168(11):597-608.
 
101 - Javaid G (2004)
Javaid G, Shah OJ, Dar MA, Shah P, Wani NA, Zargar SA. Role of endoscopic ultrasonography in preoperative staging of gastric carcinoma. ANZ J Surg 2004; 74(3):108-11.
 
102 - Jeurnink SM (2007)
Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction. a systematic review. BMC Gastroenterol 2007; 7:18.
 
103 - Jun DW (2007)
Jun DW, Lee OY, Lim HC, Kwon SJ, Lee HL, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH. Role of computed tomographic colonoscopy of postoperative surveillance in patient with gastric cancer. World J Gastroenterol 2007; 13(11):1646-51.
 
104 - Jüni P (2003)
Jüni P, Altman DG, Egger M: Assessing the quality of randomised controlled trials; in: Egger M, Davey SG, Altman DG, (eds): Systematic Reviews in Health Care. Meta-analysis in context. London BMJ 2003.
 
105 - Kaiser GM (2007)
Kaiser GM, Sotiropoulos GC, Fruhauf NR, Stavrou GA, Peitgen K, Pottgen C, Gerken G, Paul A, Broelsch CE. Value of staging laparoscopy for multimodal therapy planning in esophago-gastric cancer. Int Surg 2007; 92(3):128-32.
 
106 - Kamei H (2005)
Kamei H, Hachisuka T, Nakao M, Takagi K. Quick recovery of serum diamine oxidase activity in patients undergoing total gastrectomy by oral enteral nutrition. Am J Surg 2005; 189(1):38-43.
 
107 - Kang I (2007)
Kang I, Kim YS, Kim C. Mineral deficiency in patients who have undergone gastrectomy. Nutrition 2007; 23(4):318-22.
 
108 - Kasakura Y (2002)
Kasakura Y, Mochizuki F, Wakabayashi K, Kochi M, Fujii M, Takayama T. An evaluation of the effectiveness of extended lymph node dissection in patients with gastric cancer. a retrospective study of 1403 cases at a single institution. J Surg Res 2002; 103(2):252-9.
 
109 - Kayaalp C (2002)
Kayaalp C, Arda K, Orug T, Ozcay N. Value of computed tomography in addition to ultrasound for preoperative staging of gastric cancer. Eur J Surg Oncol 2002; 28(5):540-3.
 
110 - Kelly S (2001)
Kelly S, Harris KM, Berry E, Hutton J, Roderick P, Cullingworth J, Gathercole L, Smith MA. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49(4):534-9.
 
111 - Kim S (2005)
Kim S1, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85. Epub 2005 Aug 15.
 
112 - Kim HS (2000)
Kim HS, Lee DK, Baik SK, Kim JM, Kwon SO, Kim DS, Cho MY. Endoscopic mucosal resection with a ligation device for early gastric cancer and precancerous lesions. comparison of its therapeutic efficacy with surgical resection. Yonsei Med J 2000; 41(5):577-83.
 
113 - Kim JJ (2007)
Kim JJ, Lee JH, Jung HY, Lee GH, Cho JY, Ryu CB, Chun HJ, Park JJ, Lee WS, Kim HS, Chung MG, Moon JS, Choi SR, Song GA, Jeong HY, Jee SR, Seol SY, Yoon YB. EMR for early gastric cancer in Korea. A multicenter retrospective study. Gastrointest Endosc 2007; 66(4):693-700.
 
114 - Kim SH (1999)
Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33.
 
115 - King PM (2004)
King PM, Blazeby JM, Gupta J, Alderson D, Moorghen M. Upper gastrointestinal cancer pathology reporting: a regional audit to compare standards with minimum datasets. J Clin Pathol 2004 July;57(7):702-5.
 
116 - Kiyama T (2005)
Kiyama T, Mizutani T, Okuda T, Fujita I, Tokanaga A, Tajiri T et al. Postoperative changes in body composition after gastrectomy. J Gastrointest Surg 2005; 9(3):313-9.
 
117 - Kodera Y (2002)
Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002 Dec;195(6):855-64
 
118 - Kodera Y (2003)
Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003; 10(8):898-902.
 
119 - Kodera Y (2005)
Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92(9):1103-9.
 
120 - Koizumi W (2004)
Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, Ohno N, Kurihara M. Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Res 2004; 24(4):2465-70.
 
121 - Kondo H (2001)
Kondo H, Gotoda T, Ono H, Oda I, Yamaguchi H, Saito D, Yoshida S. Early gastric cancer. Endoscopic mucosal resection. Ann Ital Chir 2001; 72(1):27-31.
 
122 - Kono K (2002)
Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer. A randomized trial. Clin Cancer Res 2002; 8(6):1767-71.
 
123 - Kulig J (2007)
Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer. an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193(1):10-5.
 
124 - Kunisaki C (2003)
Kunisaki C, Shimada H, Akiyama H, Nomura M, Matsuda G, Ono H. Survival benefit of palliative gastrectomy in advanced incurable gastric cancer. Anticancer Res 2003; 23(2C):1853-8.
 
125 - Kunisaki C (2006)
Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, Shimada H. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma. a multi-institutional study. Ann Surg Oncol 2006; 13(5):659-67.
 
126 - Kunisaki C (2008)
Kunisaki C, Makino H, Akiyama H, Otsuka Y, Ono HA, Kosaka T et al. Clinical significance of the metastatic lymph-node ratio in early gastric cancer. J Gastrointest Surg 2008 March;12(3):542-9
 
127 - Kwee RM (2007)
Kwee RM, Kwee TC. Imaging in local staging of gastric cancer. a systematic review. J Clin Oncol 2007; 25(15):2107-16.
 
128 - Lagergren J (2000)
Lagergren J, Bergström R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer. 2000 Feb 1;85(3):340-6.
 
129 - Lehnert T (2004)
Lehnert T, Buhl K. Techniques of reconstruction after total gastrectomy for cancer. Br J Surg 2004; 91(5):528-39.
 
130 - Lobo DN (2006)
Lobo DN, Williams RN, Welch NT, Aloysius MM, Nunes QM, Padmanabhan J, Crowe JR, Iftikhar SY, Parsons SL, Neal KR, Allison SP, Rowlands BJ. Early postoperative jejunostomy feeding with an immune modulating diet in patients undergoing resectional surgery for upper gastrointestinal cancer. A prospective, randomized, controlled, double-blind study. Clin Nutr 2006; 25(5):716-26.
 
131 - Lundegĺrdh G (1994)
Lundegårdh G, Adami HO, Helmick C, Zack M. Risk of cancer following partial gastrectomy for benign ulcer disease. Br J Surg. 1994 Aug;81(8):1164-7.
 
132 - Lutz MP (2007)
Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, Balleisen L, Joossens E, Jansen RL, Debois M, Bethe U, Praet M, Wils J, Van CE. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer. randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25(18):2580-5.
 
133 - Macdonald JS (2001)
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10):725-30.
 
134 - Maehara Y (2002)
Maehara Y, Kakeji Y, Koga T, Emi Y, Baba H, Akazawa K et al. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery 2002 Jan;131(1 Suppl):S85-S91.
 
135 - Maeta M (1999)
Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, Ikeguchi M, Kaibara N. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125(3):325-31.
 
136 - Macintyre IM (1994)
Macintyre IM, O'Brien F. Death from malignant disease after surgery for duodenal ulcer. Gut. 1994 Apr;35(4):451-4.
 
137 - Mansour JC (2007)
Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007 Dec;14(12):3412-8.
 
138 - Marchet A (2008)
Marchet A, Mocellin S, Ambrosi A, de MG, Di LA, Marrelli D et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol 2008 Feb;34(2):159-65
 
139 - Mari E (2000)
Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer. a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11(7):837-43.
 
140 - Marrelli D (2001)
Marrelli D, Pinto E, De SA, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001; 181(1):16-9.
 
141 - Marubini E (2002)
Marubini E, Bozzetti F, Miceli R, Bonfanti G, Gennari L. Lymphadenectomy in gastric cancer. prognostic role and therapeutic implications. Eur J Surg Oncol 2002; 28(4):406-12.
 
142 - Mathus-Vliegen EMH (1994)
Mathus-Vliegen EMH, Tjioe M. Functionele en metabole gevolgen van maagoperaties. Ned Tijdschr Diëtisten 1994;49(2):28-33.
 
143 - Matsushita M (1997)
Matsushita M, Hajiro K, Okazaki K, Takakuwa H. Endoscopic mucosal resection of gastric tumors located in the lesser curvature of the upper third of the stomach. Gastrointest Endosc 1997; 45(6):512-5.
 
144 - May A (2004)
May A, Gunter E. Roth F, Gossner L. Stolte M, Vieth M et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography; a comparative, prospective, and blinded trial. Gut 2004;53:634-40.
 
145 - McCulloch P (2003)
McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003;(4):CD001964.
 
146 - Medina-Franco H (2004)
Medina-Franco H, Contreras-Saldivar A, Ramos-De La MA, Palacios-Sanchez P, Cortes-Gonzalez R, Ugarte JA. Surgery for stage IV gastric cancer. Am J Surg 2004; 187(4):543-6.
 
147 - Meining A (2003)
Meining A, Rosch T, Wolf A, Lorenz R, Allescher HD, Kauer W, Dittler HJ. High interobserver variability in endosonographic staging of upper gastrointestinal cancers. Z Gastroenterol 2003; 41(5):391-4.
 
148 - Mellemkjaer L (1996)
Mellemkjaer L, Gridley G, Møller H, Hsing AW, Linet MS, Brinton LA, et al. Pernicious anaemia and cancer risk in Denmark. Br J Cancer. 1996 Apr;73(8):998-1000.
 
149 - Mimura Y (1997)
Mimura Y, Yamakawa M, Maeda J, Tateno I, Araki S, Fujita T, Sugizaki K, Furuya K, Oohara T. Efficacy of amino acid infusion for improving protein metabolism after surgery. a prospective randomized study in patients undergoing subtotal gastrectomy. J Am Coll Surg 1997; 185(2):163-71.
 
150 - Mittal A (2004)
Mittal A, Windsor J, Woodfield J, Casey P, Lane M. Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg 2004; 91(2):205-9.
 
151 - Miyata M (2000)
Miyata M, Yokoyama Y, Okoyama N, Joh T, Seno K, Sasaki M, Ohara H, Nomura T, Kasugai K, Itoh M. What are the appropriate indications for endoscopic mucosal resection for early gastric cancer? Analysis of 256 endoscopically resected lesions. Endoscopy 2000; 32(10):773-8.
 
152 - Mochiki E (2004)
Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004; 28(3):247-53.
 
153 - Moehler M (2005)
Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92(12):2122-8.
 
154 - Moon YW (2007)
Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy. a 15-year follow-up study at a single korean institute. Ann Surg Oncol 2007; 14(10):2730-7.
 
155 - Nakajima T (2002)
Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002; 5(1):1-5.
 
156 - Nakajima T (2007)
Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94(12):1468-76.
 
157 - Nakata Y (1999)
Nakata Y, Kimura K, Tomioka N, Sato M, Watanabe Y, Kawachi K. Gastric exclusion for unresectable gastric cancer. Hepatogastroenterology 1999; 46(28):2654-7.
 
158 - Nashimoto A (2003)
Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer. Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21(12):2282-7.
 
159 - Nasu J (2006)
Nasu J, Nishina T, Hirasaki S, Moriwaki T, Hyodo I, Kurita A, Nishimura R. Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers. J Clin Gastroenterol 2006; 40(5):412-5.
 
160 - Nitti D (2006)
Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, Tres A, Coombes RC, Crivellari D, Marchet A, Sanchez E, Bliss JM, Homewood J, Couvreur ML, Hall E, Baron B, Woods E, Emson M, Van CE, Lise M. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006; 17(2):262-9.
 
161 - Nomura E (2003)
Nomura E, Tsukuma H, Ajiki W, Oshima A. Population-based study of relationship between hospital surgical volume and 5-year survival of stomach cancer patients in Osaka, Japan. Cancer Sci 2003; 94(11):998-1002.
 
162 - Oda I (2006)
Oda I, Saito D, Tada M, Iishi H, Tanabe S, Oyama T, Doi T, Otani Y, Fujisaki J, Ajioka Y, Hamada T, Inoue H, Gotoda T, Yoshida S. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006; 9(4):262-70.
 
163 - Oehler C (2006)
Oehler C, Ciernik IF. Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treat Rev 2006; 32(2):119-38.
 
164 - Offerhaus (1992)
Offerhaus GJ, Tersmette AC, Giardiello FM, Huibregtse K, Vandenbroucke JP, Tytgat. Evaluation of endoscopy for early detection of gastric-stump cancer. Lancet 1992 Jul 4;340(8810):33-5.
 
165 - Oka S (2006)
Oka S, Tanaka S, Kaneko I, Mouri R, Hirata M, Kawamura T, Yoshihara M, Chayama K. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006; 64(6):877-83.
 
166 - Okada M (1983)
Okada M, Kojima S, Murakami M, Fuchigami T, Yao T, Omae T et al. Human gastriccarcinoma: prognosis in relation to macroscopic and microscopic features of the primary tumor. J Natl Cancer Inst 1983 Aug;71(2):275-9
 
167 - Ouchi K (1998)
Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, Yamanami H. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998; 69(1):41-4.
 
168 - Panzini I (2002)
Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P et al: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88(1):21-27.
 
169 - Park SH (2008)
Park SH, Nam E, Park J, Cho EK, Shin DB, Lee JH, Lee WK, Chung M, Lee SI. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol 2008; 19(4):729-33.
 
170 - Peeters M (2008)
Peeters M, Lerut T, Vlayen J, Mambourg F, Ectors N, Deprez P, et al. Wetenschappelijke ondersteuning van het College voor Oncologie. een nationale praktijkrichtlijn voor de aanpak van slokdarm- en maagkanker. Good Clinical Practice (GCP). 2008. Brussel, Federaal Kenniscentrum voor de Gezondheidszorg (KCE). KCE Reports 75A (D/2008/10.273/16).
 
171 - Persiani R (2008)
Persiani R, Rausei S, Biondi A, Boccia S, Cananzi F, D'Ugo D. Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol 2008 May;34(5):519-24.
 
172 - Pinto-de-Sousa J (2001)
Pinto-de-Sousa J, David L, Seixas M, Pimenta A. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg 2001;18(2):102-10.
 
173 - Popiela T (2004)
Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004; 7(4):240-5.
 
174 - Quarticelli T (2004)
Quarticelli T, Scardapane A, Memeo M, Calbi R, Stabile Ianora AA, Angelelli G. Multidetector CT assessment of postgastrectomy patients. Radiol Med (Torino) 2004; 107(4):317-24.
 
175 - Reynolds JV (1997)
Reynolds JV, Kanwar S, Welsh FK, Windsor AC, Murchan P, Barclay GR, Guillou PJ. 1997 Harry M. Vars Research Award. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? J Parenter Enteral Nutr 1997; 21(4):196-201.
 
176 - Rosen HR (1998)
Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P et al: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16(8):2733-8.
 
177 - Roth AD (2007)
Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de BF. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma. a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007; 25(22):3217-23.
 
178 - Roukos DH (2001)
Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001 June 15;84(12):1602-9.
 
179 - Ryan AM (2006)
Ryan AM, Rowley SP, Healy LA, Floeed PM, Ravi N, Reynolds JV. Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit.Clinical Nutrition (2006) 25,386–93.
 
180 - Sadighi S (2006)
Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer. a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006; 6:274.
 
181 - Safatle-Ribeiro AV (1998)
Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC. Gastric stump cancer: what is the risk? Dig Dis 1998;16:159-68.
 
182 - Saito H (2008)
Saito H, Fukumoto Y, Osaki T, Yamada Y, Fukuda K, Tatebe S et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol 2008 Feb 1;97(2):132-5.
 
183 - Sakamoto J (2002)
Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer. a meta-analysis of centrally randomized controlled clinical trials. J Immunother 2002; 25(5):405-12.
 
184 - Sakuramoto S (2007)
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357(18):1810-20.
 
185 - Sakuta H (2005)
Sakuta H, Suzuki T, Yasuda H, Wakiyama H, Hase K. Plasma vitamin B12, folate and homocysteine levels in gastrectomized men. Clin Nutr 2005; 24(2):244-9.
 
186 - Sand J (1997)
Sand J, Luostarinen M, Matikainen M. Enteral or parenteral feeding after total gastrectomy. prospective randomised pilot study. Eur J Surg 1997; 163(10):761-6.
 
187 - Sano T (2004)
Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery. morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22(14):2767-73.
 
188 - Sasako M (2008)
Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453-62.
 
189 - Sastre J (2006)
Sastre J, Garcia-Saenz JA, az-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006;12(2):204-13.
 
190 - Sato Y (2004)
Sato Y, Kondo M, Kohashi S, Takahashi N, Takahashi S, Sinohara T, Ono K, Matsuda M, Ryoma Y, Shiroto H, Kondo Y, Uchino J, Saito K, Todo S. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother 2004; 27(5):394-7.
 
191 - Sautner T (1994)
Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12(5):970-4.
 
192 - Schlemper RJ (1997)
Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, Sipponen P, Stolte M, Watanabe H, Takahashi H, Fujita R. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997; 349(9067):1725-9.
 
193 - Schlemper RJ (2000)
Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47(2):251-6.
 
194 - Senkal M (1995)
Senkal M, Kemen M, Homann HH, Eickhoff U, Baier J, Zumtobel V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg 1995;161(2):115-22.
 
195 - Shen JY (2007)
Shen JY, Kim S, Cheong JH, Kim YI, Hyung WJ, Choi WH et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer 2007 Aug 15;110(4):745-51.
 
196 - Shimada S (2001)
Shimada S, Yagi Y, Shiomori K, Honmyo U, Hayashi N, Matsuo A, Marutsuka T, Ogawa M. Characterization of early gastric cancer and proposal of the optimal therapeutic strategy. Surgery 2001;129(6):714-19.
 
197 - Shinohara T (2005)
Shinohara T, Ohyama S, Yamaguchi T, Muto T, Kohno A, Kato Y, Urashima M. Clinical value of multidetector row computed tomography in detecting lymph node metastasis of early gastric cancer. Eur J Surg Oncol 2005; 31(7):743-8.
 
198 - Siewert JR (1998)
Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998 Oct;228(4):449-61.
 
199 - SIGN (2006)
SIGN. Management of oesphageal and gastric cancer. A national clinical guideline. 2006. Edinburgh, Scottish Intercollagiate Guidelines Network. http://www.sign.ac.uk/pdf/sign87.pdf
 
200 - Sinning C (2007)
Sinning C, Schaefer N, Standop J, Hirner A, Wolff M. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol 2007;33(2):133-39.
 
201 - Smith DD (2005)
Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005 Oct 1;23(28):7114-24.
 
202 - Song SY (2004)
Song SY, Park S, Kim S, Son HJ, Rhee JC. Characteristics of intramucosal gastric carcinoma with lymph node metastatic disease. Histopathology 2004;44(5):437-44.
 
203 - Songun I (1996)
Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer. 1996 Mar;32A(3):433-7
 
204 - Stolte M (2003)
Stolte M. The new Vienna classification of epithelial neoplasia of the gastrointestinal tract. Advantages and disadvantages. Virchows Arch 2003;442(2):99-106.
 
205 - Tajima Y (2004)
Tajima Y, Yamazaki K, Nishino N, Morohara K, Yamazaki T, Kaetsu T, Suzuki S, Kawamura M, Kumagai K, Kusano M. Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions. Br J Cancer 2004;91(7):1342-8.
 
206 - Takahashi Y (2003)
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients. A prospective clinical study. Gastric Cancer 2003;6(3):142-5.
 
207 - Tan IT (2007)
Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol 2007;96(6):503-6.
 
208 - Tani N (2007)
Tani N, Ichikawa D, Ikoma D, Tomita H, Sai S, Ikoma H, Okamoto K, Ochiai T, Ueda Y, Otsuji E, Yamagishi H, Miura N, Shiota G. Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. Anticancer Res 2007;27(2):1207-12.
 
209 - Tebbutt NC (2002)
Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002;13(10):1568-75.
 
210 - Teng XJ (2006)
Teng XJ, Shen ZX, Xiang JJ, Shen L, Yuan L, Guo J, Wang XL. Pre- and post-operative plasma big endothelin-1 levels in patients with gastric carcinoma undergoing radical gastrectomy. Anticancer Res 2006; 26(3B):2503-7.
 
211 - Tentes AA (2006)
Tentes AA, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, Dimitriou T. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbecks Arch Surg 2006; 391(2):124-9.
 
212 - Tersmette AC (1990)
Tersmette AC, Offerhaus GJ, Tersmette KW, Giardiello FM, Moore GW, Tytgat GN et al. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 1990 Oct 15;50(20):6486-9.
 
213 - Thuss-Patience PC (2005)
Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma. A randomized phase II study. J Clin Oncol 2005;23(3):494-501.
 
214 - Trumper M (2006)
Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer. A pooled analysis of three clinical trials. Eur J Cancer 2006;42(7):827-34.
 
215 - Tsujinaka T (2001)
Tsujinaka T, Shiozaki H, Yano M, Kikkawa N, Takami M, Monden M. Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy. Oncol Rep 2001 Jan;8(1):33-8.
 
216 - Tsujitani S (1999)
Tsujitani S, Oka S, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Less invasive surgery for early gastric cancer based on the low probability of lymph node metastasis. Surgery 1999;125(2):148-54.
 
217 - Ueda H (2006)
Ueda H, Ito M, Tanaka S, Oka S, Takata S, Imagawa S, Xie XF, Yoshihara M, Haruma K, Chayama K. The effect of Helicobacter pylori eradication therapy on gastric ulcer healing after endoscopic mucosal resection. J Clin Gastroenterol 2006; 40(4):293-6.
 
218 - Uedo N (2007)
Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, Kato M, Tatsumi K, Masuda E, Tamai C, Yamamoto S, Higashino K, Iishi H, Tatsuta M. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer. A prospective randomized controlled trial. Am J Gastroenterol 2007;102(8):1610-6.
 
219 - Van Cutsem E (2006)
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer. A report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7.
 
220 - Verschuur EM (2006)
Verschuur EM, Steyerberg EW, Kuipers EJ, Tilanus HW, Siersema PD. Follow-up after surgical treatment for cancer of the gastrointestinal tract. Dig Liver Dis 2006; 38(7):479-84.
 
221 - Doornik N (2081)

Doornink N, Vogel J, Wipkink A, Beijer S. Leidraad voor voedingsdeskundigen bij kanker. 4e editie 2006, Uitgeverij De Toorts ISBN 9060208161

 
222 - Wagner AD (2005)
Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005;(2):CD004064.
 
223 - Wagner AD (2006)
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer. a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24(18):2903-9.
 
224 - Wang YP (2006)
Wang YP, Bennett C, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2006;(1):CD004276.
 
225 - Watanabe K (2006)
Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric tumors. Historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. Gastrointest Endosc 2006;63(6):776-82.
 
226 - Watanabe Y (2006)
Watanabe Y, Kato N, Maehata T, Okamoto M, Tsuda T, Hattori S, Yamauchi S, Fujita K, Baba S, Nakaya S, Inaba H, Kitajima S, Suzuki M, Niwa H, Itoh F. Safer endoscopic gastric mucosal resection. Preoperative proton pump inhibitor administration. J Gastroenterol Hepatol 2006; 21(11):1675-80.
 
227 - Whiting J (2006)
Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer. A review. Gastric Cancer 2006;9(2):74-81.
 
228 - Wohrer SS (2004)
Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15(11):1585-95.
 
229 - Wong BC (2004)
Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al.; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004 Jan 14;291(2):187-94.
 
230 - Wu CW (2006)
Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer. A randomised controlled trial. Lancet Oncol 2006;7(4):309-15.
 
231 - Wu CW (2006)
Wu CW, Chang IS, Lo SS, Hsieh MC, Chen JH, Lui WY, Whang-Peng J. Complications following D3 gastrectomy. Post hoc analysis of a randomized trial. World J Surg 2006;30(1):12-6.
 
232 - Xu DZ (2004)
Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004;10(18):2727-30.
 
233 - Xu W (2005)
Xu W, Zhang MW, Huang J, Wang X, Xu SF, Li Y, Wang SJ. Correlation between CK18 gene and gastric carcinoma micrometastasis. World J Gastroenterol 2005;11(41):6530-4.
 
234 - Yamaguchi Y (2005)
Yamaguchi Y, Katsumi N, Tauchi M, Toki M, Nakamura K, Aoki K, Morita Y, Miura M, Morozumi K, Ishida H, Takahashi S. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. Aliment Pharmacol Ther 2005; 21 Suppl 2:111-5.
 
235 - Yan TD (2007)
Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007;14(10):2702-13.
 
236 - Ye BD (2006)
Ye BD, Cheon JH, Choi KD, Kim SG, Kim JS, Jung HC, Song IS. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection. A prospective randomized controlled trial. Aliment Pharmacol Ther 2006; 24(5):837-43.
 
237 - Ye W (2003)
Ye W, Nyrén O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut. 2003 Jul;52(7):938-41.
 
238 - Yokota T (1999)
Yokota T, Kunii Y, Teshima S, Yamada Y, Saito T, Takahashi M et al. Significant prognostic factors in patients with node-negative gastric cancer. Int Surg 1999 Oct;84(4):331-6
 
239 - Yokota T (2002)
Yokota T, Ishiyama S, Saito T, Teshima S, Yamada Y, Iwamoto K et al. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res 2002 Nov;22(6B):3673-7.
 
240 - Yonemura Y (1996)
Yonemura Y, Kinoshita K, Fujimura T, Fushida S, Sawa T, Matsuki N et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996 Sep;43(11):1260-72.
 
241 - Yoo SY (2003)
Yoo SY, Kim KW, Han JK, Kim AY, Lee HJ, Choi BI. Helical CT of postoperative patients with gastric carcinoma. value in evaluating surgical complications and tumor recurrence. Abdom Imaging 2003; 28(5):617-23.
 
242 - Yu W (2006)
Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93(5):559-63.
 
243 - Yun M (2005)
Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD. Lymph node staging of gastric cancer using (18)F-FDG PET. a comparison study with CT. J Nucl Med 2005; 46(10):1582-8.
 
244 - Zhao S-L (2008)
Zhao S-L,Fang J-Y. The role of postoperative adjuvant chemotherapy folowing curative resection for gastric cancer: a meta-analysis. Cancer Invest 2008 Apr-May;26(3):317-25.
 
245 - Zhang XF (2004)
Zhang XF, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, Zhang JZ, Zheng CH. Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol 2004;10(23):3405-8.
 
246 - Ziegler F (1998)
Ziegler F, Nitenberg G, Coudray-Lucas C, Lasser P, Giboudeau J, Cynober L. Pharmacokinetic assessment of an oligopeptide-based enteral formula in abdominal surgery patients. Am J Clin Nutr 1998; 67(1):124-8.
 
247 - Sobin (2002)
Sobin LH, Wittekind CH, editors. International Union Against Cancer. TNM classification of malignant tumours. 6th revised edition. New York: John Wiley&Sons Ltd., 2002.
 
248 - Kanematsu (2006)

Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y et al. Imaging liver metastases: review and update. Eur J Radiol 2006;58:217-28.

 
249 - Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) (2004)

Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), Recommandations pour la pratique clinique: standards, options et recommandations 2003 pour la prise en charge des patients atteints d'adénocarcinomes de l'estomac (cancers du cardia, autres types histologiques exclus), in Standards, Options et Recommendations. 2004, FNCLCC, Paris

 
250 - Davies J (1997)
Davies J, Chalmers AG, Sue-Ling HM, May J, Miller GV, Martin IG et al. Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 1997;41:314-9.
 
251 - Barry JD (2002)
Barry JD, Edwards P, Lewis WG, Dhariwal D, Thomas GV. Special interest radiology improves the perceived preoperative stage of gastric cancer. Clinical Radiology 2002;57:984-8.
 
252 - Chen CY (2007)
Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS et al. Gastric cancer: preoperative local staging with 3D multidetector row CT - correlation with surgical and histopathologic results. Radiology 2007; 242:472-82
 
253 - D'Elia FD (2000)
D'Elia FD, Zingarelli A, Palli D, Grani M. Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases. Eur Radiol 2000;10:1877-85.
 
254 - Dux M (1999)
Düx M, Richter GM, Hansmann J, Kuntz C, Kauffmann GW. Helical Hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr 1999; 23: 913-22.
 
255 - Kamel HR (2004)
Kamel HR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J 2004;10:104-20.
 
256 - Kim YN (2009)
Kim YN, Choi D, Kim SH, Kim MJ, Lee SJ, Lee WJ et al. Gastric cancer staging at isotropic MDCT including coronal and sagittal MPR images: endoscopically diagnosed early vs.advanced gastric cancer. Abdom Imaging 2009 Jan-Feb34 (1);26-34.
 
257 - Bouvier AM (2002)
Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002 June 1;94(11):2862-6.
 
258 - CBO Evidenc-based (2007)
CBO. Evidence-based richtlijnontwikkeling. Handleiding voor werkgroepleden. 2007. Utrecht, Kwaliteitsinstituut voor Gezondheidszorg CBO.
 
259 - Japanese Classification (1998)
Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma -2nd English Edition-. Gastric Cancer 1998; 1(1):10-24.
 
260 - Introduction to JGCA (2001)
Japanese Gastric Cancer Association. Introduction to JGCA gastric cancer treatment guidelines. 2001. Kyoto Japan, JGCA.
 
261 - NCCN (2008)
NCCN (National Clinical Cancer Network) Clinical Practice Guidelines in Oncology. Gastric Cancer 2008. http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf.
 
262 - SIGN 2006 (2006)

SIGN. Management of oesphageal and gastric cancer. A national clinical guideline. 2006. Edinburgh, Scottish Intercollagiate Guidelines Network. http://www.sign.ac.uk/pdf/sign87.pdf

 
263 - Paris endoscopic (2003)
The Paris endoscopic classifications of syperficial neplastic lesions: esophagus, stomach, and colon. November 30 to December 1, 2002, Gastrointest Endosc 2003;58:S3-S4
 
264 - Updat Paris Classification (2005)
Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005;37:570-8.
 
265 - WHO classification 2000 (2000)
World health organization classification of tumours. Pathology & genetics. Tumours of the digestive system. Lyon: IARC press; 2000.
 
266 - Dicken BJ 2005 (2005)

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005 Jan;241(1):27-39.

 
267 - Eeftinck Schattenkerk M 1983 (1983)
Eeftinck Schattenkerk M, Obertrop H, Bruining HA, van Rooyen W, van Houten H. Needle catheter jejunostomy (NCJ) for early postoperative feeding: experience in 210 patients. Neth J Surg 1983 35(5):163-6.
 
268 - Chen CY 2007 (2007)
Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS et al. Gastric cancer: preoperative local staging with 3D multidetector row CT - correlation with surgical and histopathologic results. Radiology 2007; 242: 472-82.
 
269 - Barry JD 2002 (2002)
Barry JD, Edwards P, Lewis WG, Dhariwal D, Thomas GV. Special interest radiology improves the perceived preoperative stage of gastric cancer. Clinical Radiology 2002; 57: 984-8.
 
270 - Dux M 1999 (1999)
Düx M, Richter GM, Hansmann J, Kuntz C, Kauffmann GW. Helical Hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr 1999; 23: 913-22
 
271 - FNCLCC 2004 (2004)
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), Recommandations pour la pratique clinique: standards, options et recommandations 2003 pour la prise en charge des patients atteints d'adénocarcinomes de l'estomac (cancers du cardia, autres types histologiques exclus), in Standards, Options et Recommendations. 2004, FNCLCC, Paris.
 
272 - Kamel HR 2004 (2004)
Kamel HR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J 2004; 10: 104-20.
 
273 - Kim YN 2008 (2009)
Kim YN, Choi D, Kim SH, Kim MJ, Lee SJ, Lee WJ et al. Gastric cancer staging at isotropic MDCT including coronal and sagittal MPR images: endoscopically diagnosed early vs.advanced gastric cancer. Abdom Imaging 2009: Jan-Feb;34(1):26-34.
 
274 - Bouvier AM 2002 (2002)
Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002 June 1;94(11):2862-6.
 
275 - Burbidge S (2013)
Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clinical radiology. 2013;68(3):251-5 [link]
 
276 - Dalal KM (2008)
Dalal KM, Woo Y, Kelly K et al. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2008;11(4):206-13 [link]
 
277 - Huang H (2014)
Huang H, Jin JJ, Long ZW et al. Three-port laparoscopic exploration is not sufficient for patients with T4 gastric cancer. Asian Pacific journal of cancer prevention : APJCP. 2014;15(19):8221-4 [link]
 
278 - Kakroo SM (2013)
Kakroo SM, Rashid A, Wani AA et al. Staging Laparoscopy in Carcinoma of Stomach: A Comparison with CECT Staging. International journal of surgical oncology. 2013;2013:674965 [link]
 
279 - Kapiev A (2010)
Kapiev A, Rabin I, Lavy R et al. The role of diagnostic laparoscopy in the management of patients with gastric cancer. The Israel Medical Association journal : IMAJ. 2010;12(12):726-8 [link]
 
280 - Kikuchi H (2014)
Kikuchi H, Kamiya K, Hiramatsu Y et al. Laparoscopic narrow-band imaging for the diagnosis of peritoneal metastasis in gastric cancer. Annals of surgical oncology. 2014;21(12):3954-62 [link]
 
281 - Kishi K (2012)
Kishi K, Fujiwara Y, Yano M et al. Staging laparoscopy using ALA-mediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer. Journal of surgical oncology. 2012;106(3):294-8 [link]
 
282 - Kishi K (2014)
Kishi K, Fujiwara Y, Yano M et al. Diagnostic laparoscopy with 5-aminolevulinic-acid-mediated photodynamic diagnosis enhances the detection of peritoneal micrometastases in advanced gastric cancer. Oncology. 2014;87(5):257-65 [link]
 
283 - Mahadevan D (2010)
Mahadevan D, Sudirman A, Kandasami P et al. Laparoscopic staging in gastric cancer: An essential step in its management. Journal of minimal access surgery. 2010;6(4):111-3 [link]
 
284 - Mezhir JJ (2013)
Mezhir JJ, Posner MC, Roggin KK. Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. Journal of surgical oncology. 2013;107(8):794-8 [link]
 
285 - Muntean V (2009)
Muntean V, Oniu T, Lungoci C et al. Staging laparoscopy in digestive cancers. Journal of gastrointestinal and liver diseases : JGLD. 2009;18(4):461-7 [link]
 
286 - Murayama Y (2012)
Murayama Y, Ichikawa D, Koizumi N et al. Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid. Anticancer research. 2012;32(12):5421-7 [link]
 
287 - Power DG (2009)
Power DG, Schattner MA, Gerdes H et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. Journal of the American College of Surgeons. 2009;208(2):173-8 [link]
 
288 - Santa-Maria AF (2014)
Santa-Maria AF, Valadao M, Iglesias AC. The role of staging laparoscopy in treatment of locally advanced gastric cancer. Surgical laparoscopy, endoscopy & percutaneous techniques. 2014;24(5):434-9 [link]
 
289 - Shelat VG (2012)
Shelat VG, Thong JF, Seah M et al. Role of staging laparoscopy in gastric malignancies - our institutional experience. World journal of gastrointestinal surgery. 2012;4(9):214-9 [link]
 
290 - Tourani SS (2015)
Tourani SS, Cabalag C, Link E et al. Laparoscopy and peritoneal cytology: important prognostic tools to guide treatment selection in gastric adenocarcinoma. ANZ journal of surgery. 2015;85(1-2):69-73 [link]
 
291 - Tsuchida K (2011)
Tsuchida K, Yoshikawa T, Tsuburaya A et al. Indications for staging laparoscopy in clinical T4M0 gastric cancer. World journal of surgery. 2011;35(12):2703-9 [link]
 
292 - Yamagata Y (2013)
Yamagata Y, Amikura K, Kawashima Y et al. Staging laparoscopy in advanced gastric cancer: usefulness and issues requiring improvement. Hepato-gastroenterology. 2013;60(124):751-5 [link]
 
293 - Bilici A (2011)
Bilici A, Ustaalioglu BBO, Seker M et al. The role of 8F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? European Journal of Nuclear Medicine & Molecular Imaging. 2011;38(1):64-73 [link]
 
294 - Choi JY (2014)
Choi JY, Shim KN, Kim SE et al. The Clinical Value of 18F-Fluorodeoxyglucose Uptake on Positron Emission Tomography/Computed Tomography for Predicting Regional Lymph Node Metastasis and Non-curative Surgery in Primary Gastric Carcinoma. Korean Journal of Gastroenterology/Taehan Sohwagi Hakhoe Chi. 2014;64(6):340-7 [link]
 
295 - Ha TK (2011)
Ha TK, Choi YY, Song SY et al. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. Journal of The Korean Surgical Society. 2011;81(2):104-10 [link]
 
296 - Kim EY (2011)
Kim EY, Lee WJ, Choi D et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol. 2011;79(2):183-8 [link]
 
297 - Kwee R.M (2009)
Kwee R.M, Kwee T.C. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6-22
 
298 - Lee JE (2011)
Lee JE, Hong SP, Ahn DH et al. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Medical Journal. 2011;52(1):81-8 [link]
 
299 - Park K (2014)
Park K, Jang G, Baek S et al. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori. 2014;100(2):201-6 [link]
 
300 - Seevaratnam R (2013)
Seevaratnam R, Cardoso R, McGregor C et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2013;15(SUPPL.1):S3-S18 [link]
 
301 - Smyth E (2012)
Smyth E, Schoder H, Strong VE et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012;118(22):5481-8 [link]
 
302 - Wang Z (2011)
Wang Z, Chen J.-Q. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: A systematic review. BMC Gastroenterology. 2011;11 [link]
 
303 - Wu L-M (2012)
Wu L-M, Hu J-N, Hua J et al. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. Journal of Gastroenterology & Hepatology. 2012;27(3):472-80 [link]
 
304 - Yang Q-M (2008)
Yang Q-M, Kawamura T, Itoh H et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepato-Gastroenterology. 2008;55(82-83):782-5 [link]
 
305 - Al-Batran SE (2010)
Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010;116(11):2511-8 [link]
 
306 - Bang Y.-J (2010)
Bang Y.-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97 [link]
 
307 - Boku N (2009)
Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology. 2009;10(11):1063-9 [link]
 
308 - Cunningham D (2008)
Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine. 2008;358(1):36-46 [link]
 
309 - Curran D (2009)
Curran D, Pozzo C, Zaluski J et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Quality of Life Research. 2009;18(7):853-61 [link]
 
310 - Dank M (2008)
Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19(8):1450-7 [link]
 
311 - Eatock MM (2013)
Eatock MM, Tebbutt NC, Bampton CL et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(3):710-8 [link]
 
312 - Ford HE (2014)
Ford HE, Marshall A, Bridgewater JA et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology. 2014;15(1):78-86 [link]
 
313 - Fuchs CS (2014)
Fuchs CS, Tomasek J, Yong C.J et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-9 [link]
 
314 - Guimbaud R (2014)
Guimbaud R, Louvet C, Ries P et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520-6 [link]
 
315 - Higuchi K (2014)
Higuchi K, Tanabe S, Shimada K et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). European Journal of Cancer. 2014;50(8):1437-45 [link]
 
316 - Hironaka S (2013)
Hironaka S, Ueda S, Yasui H et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology. 2013;31(35):4438-44 [link]
 
317 - Iveson T (2014)
Iveson T, Donehower R.C, Davidenko I et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncology. 2014;15(9):1007-18 [link]
 
318 - Kang J.H (2012)
Kang J.H, Lee S.I, Lim D.H et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513-8 [link]
 
319 - Kim HJ (2013)
Kim HJ, Kim SY, Kim TY et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Annals of Oncology. 2013;24(11):2850-4 [link]
 
320 - Koizumi W (2014)
Koizumi W, Kim YH, Fujii M et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Journal of Cancer Research & Clinical Oncology. 2014;140(2):319-28 [link]
 
321 - Koizumi W (2013)
Koizumi W, Yamaguchi K, Hosaka H et al. Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer. 2013;109(8):2079-86 [link]
 
322 - Koopman M (2007)
Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370(9582):135-42 [link]
 
323 - Li J (2013)
Li J, Qin S, Xu J et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology. 2013;31(26):3219-25 [link]
 
324 - Liu G-F (2014)
Liu G-F, Tang D, Li P et al. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis. World Journal of Gastroenterology. 2014;20(1):310-8 [link]
 
325 - Lordick F (2013)
Lordick F, Kang Y-K, Chung H-C et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology. 2013;14(6):490-9 [link]
 
326 - Lu Y (2014)
Lu Y, Liu Z, Zhang J. S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study. Journal of Chemotherapy. 2014;26(3):159-64 [link]
 
327 - Mochiki E (2012)
Mochiki E, Ogata K, Ohno T et al. Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. British journal of cancer. 2012;107(1):31-6 [link]
 
328 - Moehler M (2010)
Moehler M, Kanzler S, Geissler M et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology. 2010;21(1):71-7 [link]
 
329 - Ohtsu A (2011)
Ohtsu A, Shah M.A, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology. 2011;29(30):3968-76 [link]
 
330 - Ohtsu A (2013)
Ohtsu A, Ajani JA, Bai Y-X et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. Journal of Clinical Oncology. 2013;31(31):3935-43 [link]
 
331 - Roy AC (2013)
Roy AC, Park SR, Cunningham D et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Annals of Oncology. 2013;24(6):1567-73 [link]
 
332 - Ryu MH (1990)
Ryu MH, Yoo C, Kim JG et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European journal of cancer (Oxford, England : 1990). 2015;51(4):482-8 [link]
 
333 - Satoh T (2014)
Satoh T, Bang Y.-J, Gotovkin E.A et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014;19(7):712-9 [link]
 
334 - Satoh T (2014)
Satoh T, Xu R-H, Cheol Chung H et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology. 2014;32(19):2039-49 [link]
 
335 - Shen L (2015)
Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168-76 [link]
 
336 - Shirao K (2013)
Shirao K, Boku N, Yamada Y et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Japanese Journal of Clinical Oncology. 2013;43(10):972-80
 
337 - Sym SJ (2013)
Sym SJ, Hong J, Park J et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemotherapy & Pharmacology. 2013;71(2):481-8 [link]
 
338 - Thuss-Patience PC (2011)
Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer. 2011;47(15):2306-14 [link]
 
339 - Waddell T (2013)
Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.[Erratum appears in Lancet Oncol. 2013 Jun;14(7):e254 Note: Frances, Alicia [corrected to Okines, Alicia Frances Clare]]. Lancet Oncology. 2013;14(6):481-9 [link]
 
340 - Wagner AD (2010)
Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews. 2010(3):Cd004064 [link]
 
341 - Wilke H (2014)
Wilke H, Muro K, Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncology. 2014;15(11):1224-35 [link]
 
342 - Xu RH (2013)
Xu RH, Sun G, Lu HS. A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2013;31:4025
 
343 - Yi JH (2012)
Yi JH, Lee J, Park SH et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer. 2012;106(9):1469-74 [link]
 
344 - Zhang Z.-D (2014)
Zhang Z.-D, Kong Y, Yang W et al. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World J Surg Oncol. 2014;12(1) [link]
 
345 - Coccolini F (2014)
Coccolini F, Cotte E, Glehen O et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. European Journal of Surgical Oncology. 2014;40(1):12-26 [link]
 
346 - http://www
http://www.ejso.com/article/S0748-7983(13)00867-6/pdf.
 
347 - Kerkar SP (2009)
Kerkar SP, Kemp CD, Duffy A et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials. 2009;10:121 [link]
 
348 - Li Y (2011)
Li Y, Yang X, Yang G et al. An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on patients with peritoneal carcinomatosis: Final results of a phase II prospective and randomized clinical trial. Journal of Clinical Oncology. 2011;29(15 SUPPL. 1) [link]
 
349 - Rudloff U (2014)
Rudloff U, Langan RC, Mullinax JE et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. Journal of Surgical Oncology. 2014;110(3):275-84 [link]
 
350 - Sun J (2012)
Sun J, Song Y, Wang Z et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC cancer. 2012;12 [link]
 
351 - Adachi S (2000)
Adachi S, Kawamoto T, Otsuka M et al. Enteral vitamin B12 supplements reverse postgastrectomy B12 deficiency. Annals of surgery. 2000;232(2):199-201 [link]
 
352 - Kim H-I (2011)
Kim H-I, Hyung WJ, Song KJ et al. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Annals of Surgical Oncology. 2011;18(13):3711-7
 
353 - Chen J (2014)
Chen J, Chen C, He Y et al. A new pN staging system based on both the number and anatomic location of metastatic lymph nodes in gastric cancer. Journal of Gastrointestinal Surgery. 2014;18(12):2080-8 [link]
 
354 - Chen JD (2013)
Chen JD, Yang XP, Shen JG et al. Prognostic improvement of reexcision for positive resection margins in patients with advanced gastric cancer. European Journal of Surgical Oncology. 2013;39(3):229-34 [link]
 
355 - Cunningham D (2006)
Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006;355(1):11-20 [link]
 
356 - Dai Q (2014)
Dai Q, Jiang L, Lin R.-J et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: A meta-analysis of randomized controlled trials. J Surg Oncol. 2014 [link]
 
357 - Dikken JL (2010)
Dikken JL, Jansen EP, Cats A et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. Journal of Clinical Oncology. 2010;28(14):2430-6 [link]
 
358 - Earle CC (1999)
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. European Journal of Cancer. 1999;35(7):1059-64 [link]
 
359 - Enestvedt CK (2009)
Enestvedt CK, Diggs BS, Shipley DK et al. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointestinal Cancer Research. 2009;3(6):233-8 [link]
 
360 - Hoffman KE (2012)
Hoffman KE, Neville BA, Mamon HJ et al. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer. 2012;118(1):248-57 [link]
 
361 - Huang YY (2013)
Huang YY, Yang Q, Zhou SW et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis (Provisional abstract). PloS one. 2013;8(7):e68939 [link]
 
362 - Jacome A.A.A (2013)
Jacome A.A.A, Wohnrath D.R, Scapulatempo Neto C et al. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer. 2013;16(2):233-8 [link]
 
363 - Kim S (2005)
Kim S, Lim D.H, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. International Journal of Radiation Oncology Biology Physics. 2005;63(5):1279-85 [link]
 
364 - http://www
http://www.redjournal.org/article/S0360-3016(05)00813-8/abstract.
 
365 - Knight G (2013)
Knight G, Earle C.C, Cosby R et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: A systematic review and practice guideline for North America. Gastric Cancer. 2013;16(1):28-40 [link]
 
366 - http://download
http://download.springer.com/static/pdf/896/art%253A10.1007%252Fs10120-012-0148-3.pdf?auth66=1421341189_a0140ec2205aecfc7be8cdb622a0e15e&ext=.pdf
 
367 - http://download
http://download.springer.com/static/pdf/896/art%253A10.1007%252Fs10120-012-0148-3.pdf?auth66=1421652387_44aba44209da662ee630ca346fb73c72&ext=.pdf.
 
368 - Kofoed SC (2012)
Kofoed SC, Muhic A, Baeksgaard L et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg. 2012;101(1):26-31 [link]
 
369 - Lee S.J (2014)
Lee S.J, Sohn T.S, Lee J et al. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: A feasibility study. Anticancer Res. 2014;34(11):6585-91 [link]
 
370 - http://ar
http://ar.iiarjournals.org/content/34/11/6585.long.
 
371 - Lowy AM (1999)
Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Annals of Surgery. 1999;229(3):303-8 [link]
 
372 - Mari E (2000)
Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Annals of Oncology. 2000;11(7):837-43 [link]
 
373 - Min C (2014)
Min C, Bangalore S, Jhawar S et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: A meta-analysis of randomized trials. Oncology. 2014;86(2):79-85 [link]
 
374 - Park K (2014)
Park K, Jang G, Baek S et al. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori. 2014;100(2):201-6 [link]
 
375 - Seyedin S (2014)
Seyedin S, Wang P.-C, Zhang Q et al. Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: A SEER population analysis. Gastrointest Cancer Res. 2014;7(3-4):82-90 [link]
 
376 - http://www (1970)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171970/pdf/gcr82.pdf.
 
377 - Smalley SR (2012)
Smalley SR, Benedetti JK, Haller DG et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Journal of Clinical Oncology. 2012;30(19):2327-33 [link]
 
378 - http://jco
http://jco.ascopubs.org/content/30/19/2327.full.pdf.
 
379 - Snyder RA (2012)
Snyder RA, Castaldo ET, Bailey CE et al. Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy. International journal of surgical oncology. 2012;2012:307670 [link]
 
380 - Soon YY (2014)
Soon YY, Leong CN, Tey JC et al. Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis. Journal of Medical Imaging & Radiation Oncology. 2014;58(4):483-96 [link]
 
381 - Spolverato G (2015)
Spolverato G, Ejaz A, Kim Y et al. Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery. 2015 [link]
 
382 - Stiekema J (2015)
Stiekema J, Trip A.K, Jansen E.P.M et al. Does Adjuvant Chemoradiotherapy Improve the Prognosis of Gastric Cancer After an R1 Resection? Results from a Dutch Cohort Study. Ann Surg Oncol. 2015 [link]
 
383 - Stiekema J (2013)
Stiekema J, Cats A, Kuijpers A et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? European Journal of Surgical Oncology. 2013;39(7):686-93 [link]
 
384 - Strauss J (2010)
Strauss J, Hershman DL, Buono D et al. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. International Journal of Radiation Oncology, Biology, Physics. 2010;76(5):1404-12 [link]
 
385 - Tham CK (2010)
Tham CK, Choo SP, Poon DY et al. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World Journal of Gastroenterology. 2010;16(29):3709-15 [link]
 
386 - Yang Q (2013)
Yang Q, Wei Y, Chen Y.-X et al. Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with D2 lymphadenectomy. Gastroenterol Res Pract. 2013;2013 [link]
 
387 - Catalano F (2009)
Catalano F, Trecca A, Rodella L et al. The modern treatment of early gastric cancer: our experience in an Italian cohort. Surgical endoscopy. 2009;23(7):1581-6 [link]
 
388 - Chiu PW (2012)
Chiu PW, Teoh AY, To KF et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Surgical endoscopy. 2012;26(12):3584-91 [link]
 
389 - Cho JH (2015)
Cho JH, Cha SW, Kim HG et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a comparison study to surgery using propensity score-matched analysis. Surgical endoscopy. 2015 [link]
 
390 - Choi IJ (2015)
Choi IJ, Lee JH, Kim YI et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointestinal endoscopy. 2015;81(2):333-41 e1 [link]
 
391 - Choi KS (2011)
Choi KS, Jung HY, Choi KD et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointestinal endoscopy. 2011;73(5):942-8 [link]
 
392 - Etoh T (2005)
Etoh T, Katai H, Fukagawa T et al. Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointestinal endoscopy. 2005;62(6):868-71 [link]
 
393 - Hirasaki S (2008)
Hirasaki S, Kanzaki H, Matsubara M et al. Treatment of gastric remnant cancer post distal gastrectomy by endoscopic submucosal dissection using an insulation-tipped diathermic knife. World journal of gastroenterology : WJG. 2008;14(16):2550-5 [link]
 
394 - Hoteya S (2009)
Hoteya S, Iizuka T, Kikuchi D et al. Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. Journal of gastroenterology and hepatology. 2009;24(6):1102-6 [link]
 
395 - Hoteya S (2010)
Hoteya S, Iizuka T, Kikuchi D et al. Clinical advantages of endoscopic submucosal dissection for gastric cancers in remnant stomach surpass conventional endoscopic mucosal resection. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2010;22(1):17-20 [link]
 
396 - Kim DY (2014)
Kim DY, Hong SJ, Cho GS et al. Long-term efficacy of endoscopic submucosal dissection compared with surgery for early gastric cancer: a retrospective cohort study. Gut and liver. 2014;8(5):519-25 [link]
 
397 - Kim HS (2000)
Kim HS, Lee DK, Baik SK et al. Endoscopic mucosal resection with a ligation device for early gastric cancer and precancerous lesions: comparison of its therapeutic efficacy with surgical resection. Yonsei medical journal. 2000;41(5):577-83 [link]
 
398 - Min BH (2009)
Min BH, Lee JH, Kim JJ et al. Clinical outcomes of endoscopic submucosal dissection (ESD) for treating early gastric cancer: comparison with endoscopic mucosal resection after circumferential precutting (EMR-P). Dig Liver Dis. 2009;41(3):201-9 [link]
 
399 - Nakamoto S (2009)
Nakamoto S, Sakai Y, Kasanuki J et al. Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. Endoscopy. 2009;41(9):746-50 [link]
 
400 - Oda I (2006)
Oda I, Saito D, Tada M et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2006;9(4):262-70 [link]
 
401 - Oka S (2014)
Oka S, Tanaka S, Higashiyama M et al. Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-term outcomes. Surgical Endoscopy and Other Interventional Techniques. 2014;28(2):639-47 [link]
 
402 - Oka S (2006)
Oka S, Tanaka S, Kaneko I et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointestinal endoscopy. 2006;64(6):877-83 [link]
 
403 - Park CH (2014)
Park CH, Lee H, Kim DW et al. Clinical safety of endoscopic submucosal dissection compared with surgery in elderly patients with early gastric cancer: A propensity-matched analysis. Gastrointestinal endoscopy. 2014;80(4):599-609 [link]
 
404 - Pimentel-Nunes P (2014)
Pimentel-Nunes P, Mourao F, Veloso N et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. Endoscopy. 2014;46(11):933-40 [link]
 
405 - Shimura T (2007)
Shimura T, Sasaki M, Kataoka H et al. Advantages of endoscopic submucosal dissection over conventional endoscopic mucosal resection. Journal of gastroenterology and hepatology. 2007;22(6):821-6 [link]
 
406 - Song WC (2015)
Song WC, Qiao XL, Gao XZ. A comparison of endoscopic submucosal dissection (ESD) and radical surgery for early gastric cancer: a retrospective study. World J Surg Oncol. 2015;13:309 [link]
 
407 - Tanabe S (2014)
Tanabe S, Ishido K, Higuchi K et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014;17(1):130-6 [link]
 
408 - Watanabe K (2006)
Watanabe K, Ogata S, Kawazoe S et al. Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. Gastrointestinal endoscopy. 2006;63(6):776-82 [link]
 
409 - Watanabe T (2010)
Watanabe T, Kume K, Taip M et al. Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection. Hepato-gastroenterology. 2010;57(99-100):668-73 [link]
 
410 - Yokoi C (2006)
Yokoi C, Gotoda T, Hamanaka H et al. Endoscopic submucosal dissection allows curative resection of locally recurrent early gastric cancer after prior endoscopic mucosal resection. Gastrointestinal endoscopy. 2006;64(2):212-8 [link]
 
411 - Ono H, (2016)

Ono H, Yao K, Fujishiro M et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2016;28(1):3-15 #http://www.ncbi.nlm.nih.gov/pubmed/26234303.

 

 
412 - Bonenkamp JJ (1999)
Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. The New England journal of medicine. 1999;340(12):908-14 [link]
 
413 - Bonenkamp JJ (1995)
Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745-8 [link]
 
414 - Bonenkamp JJ (1992)
Bonenkamp JJ, van de Velde CJ, Sasako M et al. R2 compared with R1 resection for gastric cancer: morbidity and mortality in a prospective, randomised trial. The European journal of surgery = Acta chirurgica. 1992;158(8):413-8 [link]
 
415 - Cuschieri A (1996)
Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995-9 [link]
 
416 - Cuschieri A (1999)
Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. British journal of cancer. 1999;79(9-10):1522-30 [link]
 
417 - de Steur WO (2015)
de Steur WO, Hartgrink HH, Dikken JL et al. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. The British journal of surgery. 2015;102(11):1388-93 [link]
 
418 - Degiuli M (2004)
Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2004;30(3):303-8 [link]
 
419 - Degiuli M (2010)
Degiuli M, Sasako M, Ponti A et al. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. The British journal of surgery. 2010;97(5):643-9 [link]
 
420 - Degiuli M (2014)
Degiuli M, Sasako M, Ponti A et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. The British journal of surgery. 2014;101(2):23-31 [link]
 
421 - Dent DM (1988)
Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. The British journal of surgery. 1988;75(2):110-2 [link]
 
422 - El-Sedfy A (2015)
El-Sedfy A, Dixon M, Seevaratnam R et al. Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy. Annals of surgical oncology. 2015;22(6):1820-7 [link]
 
423 - Galizia G (2015)
Galizia G, Lieto E, De Vita F et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery. 2015;157(2):285-96 [link]
 
424 - Hartgrink HH (2004)
Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(11):2069-77 [link]
 
425 - Jiang L (2014)
Jiang L, Yang KH, Chen Y et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. The British journal of surgery. 2014;101(6):595-604 [link]
 
426 - Jiang L (2013)
Jiang L, Yang KH, Guan QL et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. Journal of surgical oncology. 2013;107(8):807-14 [link]
 
427 - Lustosa SA (2008)
Lustosa SA, Saconato H, Atallah AN et al. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta cirurgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia. 2008;23(6):520-30 [link]
 
428 - Memon MA (2011)
Memon MA, Subramanya MS, Khan S et al. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Annals of surgery. 2011;253(5):900-11 [link]
 
429 - Mocellin S (2015)
Mocellin S, McCulloch P, Kazi H et al. Extent of lymph node dissection for adenocarcinoma of the stomach. The Cochrane database of systematic reviews. 2015;8:Cd001964 [link]
 
430 - Mocellin S (2015)
Mocellin S, Nitti D. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials. Cancer treatment reviews. 2015;41(5):448-54 [link]
 
431 - Seevaratnam R (2012)
Seevaratnam R, Bocicariu A, Cardoso R et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2012;15 Suppl 1:S60-9 [link]
 
432 - Songun I (2010)
Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010;11(5):439-49 [link]
 
433 - Tanizawa Y (2010)
Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2010;13(3):137-48 [link]
 
434 - Wu CW (2006)
Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. The Lancet Oncology. 2006;7(4):309-15 [link]
 
435 - Wu CW (2004)
Wu CW, Hsiung CA, Lo SS et al. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. The British journal of surgery. 2004;91(3):283-7 [link]
 
436 - Yang SH (2009)
Yang SH, Zhang YC, Yang KH et al. An evidence-based medicine review of lymphadenectomy extent for gastric cancer. American journal of surgery. 2009;197(2):246-51 [link]
 
437 - Zheng B (2011)
Zheng B, Ma B, Yang K et al. Meta-analysis of randomized controlled trials comparing D2 and D4 lymphadenectomy for gastric cancer. European Surgery - Acta Chirurgica Austriaca. 2011;43(5):255-61 [link]
 
438 - Ha TK (2008)
Ha TK, An JY, Youn HG et al. Omentum-preserving gastrectomy for early gastric cancer. World journal of surgery. 2008;32(8):1703-8 [link]
 
440 - Hagiwara A (1998)
Hagiwara A, Sawai K, Sakakura C et al. Complete omentectomy and extensive lymphadenectomy with gastrectomy improves the survival of gastric cancer patients with metastases in the adjacent peritoneum. Hepato-gastroenterology. 1998;45(23):1922-9 [link]
 
441 - Hasegawa S (2013)
Hasegawa S, Kunisaki C, Ono H et al. Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2013;16(3):383-8 [link]
 
443 - Kim DJ (2014)
Kim DJ, Lee JH, Kim W. A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomy. World journal of surgical oncology. 2014;12(1) [link]
 
445 - Kim MC (2011)
Kim MC, Kim KH, Jung GJ et al. Comparative study of complete and partial omentectomy in radical subtotal gastrectomy for early gastric cancer. Yonsei medical journal. 2011;52(6):961-6 [link]
 
446 - Haverkamp L (2016)
 Haverkamp L, Brenkman HJ, Ruurda JP et al. The Oncological Value of Omentectomy in Gastrectomy for Cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2016;20(5):885-90 #http://www.ncbi.nlm.nih.gov/pubmed/26895951.
 
447 - Jongerius EJ (2016)
Jongerius EJ, Boerma D, Seldenrijk KA et al. Role of omentectomy as part of radical surgery for gastric cancer. The British journal of surgery. 2016;103(11):1497-503 #http://www.ncbi.nlm.nih.gov/pubmed/27550526
 
448 - Bracale U (2012)
Bracale U, Rovani M, Bracale M et al. Totally laparoscopic gastrectomy for gastric cancer: meta-analysis of short-term outcomes. Minim Invasive Ther Allied Technol. 2012;21(3):150-60 [link]
 
449 - Cai J (2011)
Cai J, Wei D, Gao CF et al. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer2011; 28(5-6):[331-7 pp.]. [link]
 
450 - Chen K (2014)
Chen K, Pan Y, Cai JQ et al. Totally laparoscopic gastrectomy for gastric cancer: a systematic review and meta-analysis of outcomes compared with open surgery. World journal of gastroenterology : WJG. 2014;20(42):15867-78 [link]
 
451 - Chen K (2013)
Chen K, Xu XW, Mou YP et al. Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World J Surg Oncol. 2013;11:182 [link]
 
452 - Chen XZ (2009)
Chen XZ, Hu JK, Yang K et al. Short-term evaluation of laparoscopy-assisted distal gastrectomy for predictive early gastric cancer: a meta-analysis of randomized controlled trials. Surg Laparosc Endosc Percutan Tech. 2009;19(4):277-84 [link]
 
453 - Chen XZ (2015)
Chen XZ, Wen L, Rui YY et al. Long-term survival outcomes of laparoscopic versus open gastrectomy for gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(4):e454 [link]
 
454 - Cheng Q (2014)
Cheng Q, Pang TC, Hollands MJ et al. Systematic review and meta-analysis of laparoscopic versus open distal gastrectomy. J Gastrointest Surg. 2014;18(6):1087-99 [link]
 
455 - Choi YY (2013)
Choi YY, Bae JM, An JY et al. Laparoscopic gastrectomy for advanced gastric cancer: are the long-term results comparable with conventional open gastrectomy? A systematic review and meta-analysis. Journal of surgical oncology. 2013;108(8):550-6 [link]
 
456 - Cui M (2015)
Cui M, Li Z, Xing J et al. A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Medical oncology (Northwood, London, England). 2015;32(10):241 [link]
 
457 - Deng Y (2015)
Deng Y, Zhang Y, Guo TK. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: A meta-analysis based on seven randomized controlled trials. Surg Oncol. 2015;24(2):71-7 [link]
 
458 - Fujii K (2003)
Fujii K, Sonoda K, Izumi K et al. T lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. Surgical endoscopy. 2003;17(9):1440-4 [link]
 
459 - Hayashi H (2005)
Hayashi H, Ochiai T, Shimada H et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surgical endoscopy. 2005;19(9):1172-6 [link]
 
460 - Hosono S (2006)
Hosono S, Arimoto Y, Ohtani H et al. Meta-analysis of short-term outcomes after laparoscopy-assisted distal gastrectomy. World journal of gastroenterology : WJG. 2006;12(47):7676-83 [link]
 
461 - http://www
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088052/pdf/wjg-12-7676.pdf.
 
462 - Huang YL (2014)
Huang YL, Lin HG, Yang JW et al. Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis. Int J Clin Exp Med. 2014;7(6):1490-9 [link]
 
463 - Huscher CG (2005)
Huscher CG, Mingoli A, Sgarzini G et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Annals of surgery. 2005;241(2):232-7 [link]
 
464 - Inokuchi M (2015)
Inokuchi M, Sugita H, Otsuki S et al. Laparoscopic distal gastrectomy reduced surgical site infection as compared with open distal gastrectomy for gastric cancer in a meta-analysis of both randomized controlled and case-controlled studies. Int J Surg. 2015;15:61-7 [link]
 
465 - Jiang J (2012)
Jiang J. Systematic review of feasibility and safety of laparoscopic gastrectomy for gastric cancer. Chinese-German Journal of Clinical Oncology. 2012;11(4):199-205 [link]
 
466 - Jiang L (2013)
Jiang L, Yang KH, Guan QL et al. Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: an update meta-analysis based on randomized controlled trials. Surgical endoscopy. 2013;27(7):2466-80 [link]
 
467 - Kim HH (2010)
Kim HH, Hyung WJ, Cho GS et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Annals of surgery. 2010;251(3):417-20 [link]
 
468 - Kim W (2015)
Kim W, Kim HH, Han SU et al. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Annals of surgery. 2015 [link]
 
469 - Kim Y-W (2008)
Kim Y-W, Baik YH, Yun YH et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Annals of surgery. 2008;248(5):721-7 [link]
 
470 - Kim Y-W (2013)
Kim Y-W, Yoon HM, Yun YH et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301). 2013;27(11):4267-76 [link]
 
471 - Kitano S (2002)
Kitano S, Shiraishi N, Fujii K et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery. 2002;131(1 Suppl):S306-11 [link]
 
472 - Kodera Y (2010)
Kodera Y, Fujiwara M, Ohashi N et al. Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. Journal of the American College of Surgeons. 2010;211(5):677-86 [link]
 
473 - Lee JH (2005)
Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results2005; 19(2):[168-73 pp.]. [link]
 
474 - Liang Y (2011)
Liang Y, Li G, Chen P et al. Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. ANZ journal of surgery. 2011;81(10):673-80 [link]
 
475 - Martinez-Ramos D (2011)
Martinez-Ramos D, Miralles-Tena JM, Cuesta MA et al. Laparoscopy versus open surgery for advanced and resectable gastric cancer: a meta-analysis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2011;103(3):133-41 [link]
 
476 - Memon MA (2008)
Memon MA, Khan S, Yunus RM et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surgical endoscopy. 2008;22(8):1781-9 [link]
 
477 - Ohtani H (2010)
Ohtani H, Tamamori Y, Noguchi K et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg. 2010;14(6):958-64 [link]
 
478 - Ohtani H (2011)
Ohtani H, Tamamori Y, Noguchi K et al. Meta-analysis of laparoscopy-assisted and open distal gastrectomy for gastric cancer. J Surg Res. 2011;171(2):479-85 [link]
 
479 - Peng JS (2010)
Peng JS, Song H, Yang ZL et al. Meta-analysis of laparoscopy-assisted distal gastrectomy and conventional open distal gastrectomy for early gastric cancer. Chin. 2010;29(4):349-54 [link]
 
480 - Quan Y (2015)
Quan Y, Huang A, Ye M et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015 [link]
 
481 - Sakuramoto S (2013)
Sakuramoto S, Yamashita K, Kikuchi S et al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surgical endoscopy. 2013;27(5):1695-705 [link]
 
482 - Takiguchi S (2013)
Takiguchi S, Fujiwara Y, Yamasaki M et al. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg. 2013;37(10):2379-86 [link]
 
483 - Vinuela EF (2012)
Vinuela EF, Gonen M, Brennan MF et al. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Annals of surgery. 2012;255(3):446-56 [link]
 
484 - Wang Y (2014)
Wang Y, Wang S, Huang ZQ et al. Meta-analysis of laparoscopy assisted distal gastrectomy and conventional open distal gastrectomy for EGC. Surg. 2014;12(1):53-8 [link]
 
485 - Wei HB (2011)
Wei HB, Wei B, Qi CL et al. Laparoscopic versus open gastrectomy with D2 lymph node dissection for gastric cancer: a meta-analysis. Surg Laparosc Endosc Percutan Tech. 2011;21(6):383-90 [link]
 
486 - Yakoub D (2009)
Yakoub D, Athanasiou T, Tekkis P et al. Laparoscopic assisted distal gastrectomy for early gastric cancer: is it an alternative to the open approach? Surg Oncol. 2009;18(4):322-33 [link]
 
487 - Ye LY (2013)
Ye LY, Liu DR, Li C et al. Systematic review of laparoscopy-assisted versus open gastrectomy for advanced gastric cancer. J Zhejiang Univ Sci B. 2013;14(6):468-78 [link]
 
488 - Zeng YK (2012)
Zeng YK, Yang ZL, Peng JS et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Annals of surgery. 2012;256(1):39-52 [link]
 
489 - Zhang C-D (2013)
Zhang C-D, Chen S-C, Feng Z-F et al. Laparoscopic versus open gastrectomy for early gastric cancer in Asia: a meta-analysis. Surg Laparosc Endosc Percutan Tech. 2013;23(4):365-77 [link]
 
490 - Zou ZH (2014)
Zou ZH, Zhao LY, Mou TY et al. Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: A meta-analysis. World journal of gastroenterology. 2014;20(44):16750-64 [link]
 
491 - Bang YJ (2010)
Bang YJ, Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) [Internet]. 2010; 376(9742):[687-97 pp.]. [link]
 
492 - Ruschoff J (2012)
Ruschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012;25(5):637-50 [link]